Does Wegovy Change Your Mood?

The biggest misconception: Wegovy doesn't cause depression in most people

The claim you'll often see online is that GLP-1 medicines routinely cause low mood or depression. That's not what the trial data shows. In the STEP 1 study (68 weeks, over 1,900 adults) serious psychiatric adverse events were uncommon, and semaglutide performed comparably to placebo on most mood measures. The NHS medicines page for semaglutide acknowledges mood changes as a possible effect but does not list depression as a common side effect in the way nausea or constipation appears.

That doesn't mean it never happens. It means the majority of people do not experience it, and attributing low mood entirely to the injection when other life factors are in play is tricky. Weight loss itself is a significant physiological and psychological shift. Some people feel liberated; others find it unexpectedly emotional. Both are normal human responses to a changing body, not necessarily pharmacological effects of the drug.

If you want a fuller picture of how wegovy mood fits into the broader range of things people notice on semaglutide, the Wegovy side effects guide on this site covers the whole profile, grounded in the SmPC and NHS guidance.

What the MHRA and regulators are actually watching for

Regulators don't dismiss the question. The MHRA keeps GLP-1 medicines under active post-market surveillance, and the product information for Wegovy does include mood-related terms. Patients are asked to tell their prescriber if they notice low mood, depression, or (critically) any thoughts of self-harm or suicide. These are listed as reasons to seek urgent medical help, not as expected effects, but the listing matters.

There is a plausible biological thread worth understanding. GLP-1 receptors exist in parts of the brain involved in reward and motivation, not only in the gut and pancreas. Researchers are still working out exactly what this means in practice. What's clear is that the brain-gut axis is genuinely complex, and anyone who tells you semaglutide has zero effect on central nervous system function is getting ahead of the science. If you're curious about whether Wegovy affects your mood and what the evidence actually says, the honest answer is: for most people, no clinically significant mood change occurs; for some, it does, and it's worth monitoring.

You can report any suspected side effect, including mood changes, directly through the MHRA's Yellow Card scheme, this is how regulators build real-world safety data beyond trial conditions.

When mood improves on Wegovy, and why that matters too

Here's the part that rarely makes the headlines. A meaningful proportion of people in clinical programmes report improved mood, reduced anxiety, and a greater sense of control. Some of this is almost certainly linked to the weight loss itself: mobility improves, sleep quality often gets better, and chronic health worries ease. But some researchers have proposed a more direct mechanism, with GLP-1 receptor activity potentially playing a role in the brain's dopamine and reward pathways.

This cuts both ways. If semaglutide can, in some people, nudge mood downwards, it is reasonable to think it can nudge it upwards in others. Neither effect should be exaggerated. The NHS guidance on semaglutide is measured on this point, and that measured tone is the right register. The question our prescribers hear fairly often is whether a pre-existing history of depression or anxiety rules someone out, and understanding the full picture of Wegovy mood change is part of that conversation, because the prescriber needs the full picture.

If you're weighing this up and wondering about costs alongside everything else, the Wegovy cost page sets out what private treatment typically involves in 2025 and 2026.

What to do if your mood shifts after starting Wegovy

First, tell someone. Don't sit with it. If you notice low mood, irritability, emotional flatness, or any thoughts of harming yourself, contact your prescriber that day. Don't wait for your next scheduled check-in. At nume, aftercare runs seven days a week precisely because questions don't follow office hours, the contact page has everything you need to reach the clinical team quickly.

Second, keep a rough note of when the change started relative to your dose. Did it arrive within a week of beginning treatment, or after a dose increase? That timing information helps a prescriber work out whether semaglutide is likely involved. Starting or increasing the dose is also when GI side effects peak, and persistent nausea and disrupted sleep are themselves powerful mood disruptors. Sometimes what feels like a mood change driven by the medicine is partly a mood change driven by feeling rough for ten days. The distinction matters for deciding what to do next.

Third, don't self-manage by stopping abruptly without speaking to your prescriber. Stopping a GLP-1 medicine is a clinical decision, not a switch to flip. For broader context on what makes someone a good candidate for semaglutide in the first place, the Wegovy treatment overview is a good starting point. And for a directly comparable look at how semaglutide compares to tirzepatide across a range of considerations, the weight-loss treatments page sets that out plainly.

If you'd like a clinician to review your specific situation (whether you're considering starting Wegovy or already taking it and have questions about how you're feeling) speak to our prescribers through a free consultation.